GW University Selected as First Site for High-Risk Cutaneous Squamous Cell Carcinoma Clinical Trial

GW University Selected as First Site for High-Risk Cutaneous Squamous Cell Carcinoma Clinical Trial

Industry sponsors Regeneron and Sanofi have selected George Washington University (GW) Cancer Center as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma. The study will compare disease-free survival of patients...

Pin It on Pinterest